Seroepidemiological Study of Toxoplasma gondii Infection among Psychiatric Patients in Mashhad, Northeast of Iran
,
Abstract
Background: Psychiatric patients have an increased risk of some infections like toxoplasmosis. Investigations on Toxoplasma gondii infection among psychiatric patients have been limited in Mashhad, Northeast of Iran. In this case-control study, prevalence of T. gondii was investigated by serological method.
Methods: This case-control study was performed among psychiatric patients admitted to Avicenna Hospital in Mashhad, Northeast of Iran. Three hundred and fifty inpatients and 350 controls were examined in 2012-2013 for detection of IgG and IgM antibodies against T. gondii in their blood sera by ELISA. Socio-demographic and clinical manifestations of the patients were obtained.
Results: Anti-T. gondii IgG antibodies was found in 164 (46.85%) of 350 psychiatric inpatients and 120 (34.28%) of 350 controls. Seventeen (4.85%) of psychiatric individuals and 3 (0.85%) of control group were IgM+/IgG- indicating acute form of toxoplasmosis. There were no statistically significant differences between the case and control groups. In patient group, schizophrenic patients had the highest positive rate (46.28%) and bipolar mood disorder had the second most prevalent rate (20%). Of 162 schizophrenia patients, 65 (40.1%) had latent infection which was higher than that observed in controls.
Conclusion: The prevalence of T. gondii infection among psychiatric patients suffering from schizophrenia was more in Mashhad, compared with control group.
Alvarado-Esquivel C, Urbina-Alvarez JD, Estrada-Martinez S et al. Toxoplasma gondii infection and schizophrenia: a case control study in a low Toxoplasma seroprevalence Mexican population. Parasitol Int. 2011; 60(2): 151-5.
De Hert M, Wampers M, Van Eyck D et al. Prevalence of HIV and hepatitis C infection among patients with schizophrenia. Schizophr Res. 2009; 108(1-3): 307-8.
Nakamura Y, Koh M, Miyoshi E, Ida O, et al. High prevalence of the hepatitis C virus infection among the inpatients of schizophrenia and psychoactive substance abuse in Japan. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28(3): 591-7.
Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull. 2006; 32(2): 200-2.
Wang HL, Wang GH, Li QY, Shu C, Jiang MS, Guo Y. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr Scand. 2006; 114(1): 40-8.
Wastling J, Heap S, Ferguson D. Toxoplasma gondii--keeping our guests under control. Biologist (London). 2000; 47(5): 234-8.
Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000; 30(12-13): 1217-58.
Kravetz JD, Federman DG. Toxoplasmosis in pregnancy. Am J Med. 2005; 118(3): 212-6.
Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004; 363 (9425): 1965-76.
Flegr J. How and why Toxoplasma makes us crazy. Trends Parasitol. 2013; 29(4): 156-63.
Flegr J. Effects of Toxoplasma on human behavior. Schizophr Bull. 2007; 33(3): 757-60.
Hamidinejat H, Ghorbanpoor M, Hosseini H, Alavi SM, Nabavi L, Jalali MH, et al. Toxoplasma gondii infection in first-episode and inpatient individuals with schizophrenia. Int J Infect Dis. 2010; 14(11): e978-81.
Henriquez SA, Brett R, Alexander J, Pratt J, Roberts CW. Neuropsychiatric disease and Toxoplasma gondii infection. Neur-oimmunomodulation. 2009; 16(2): 122-33.
Tamer GS, Dundar D, Yalug I, Caliskan S, Yazar S, Aker A. The schizophrenia and Toxoplasma gondii connection: infectious, immune or both? Adv Ther. 2008; 25(7): 703-9.
Alvarado-Esquivel C, Sifuentes-Alvarez A, Narro-Duarte SG et al. Seroepidemiology of Toxoplasma gondii infection in pregnant women in a public hospital in northern Mexico. BMC Infect Dis. 2006; 13;6:113.
Guy E, Dubey JP and Hill DE. Toxoplasma gondii. Smith LJ and Robertson HV, In: Food-borne Protozoan Parasites. Nova Biomedical. 2012: 167-188
Hashemi HJ, Saraei M. Seroprevalence of Toxoplasma gondii in unmarried women in Qazvin, Islamic Republic of Iran. East Mediterr Health J. 2010; 16(1): 24-8.
Salahi-Moghaddam A, Hafizi A. A serological study on Toxoplasma gondii infection among people in south of Tehran, Iran. Korean J Parasitol. 2009; 47(1): 61-3.
Assmar M, Amirkhani A, Piazak N, Hovanesian A, Kooloobandi A, Etessami R. Toxoplasmosis in Iran. Results of a seroepidemiological study. Bull Soc Pathol Exot. 1997; 90(1): 19-21.
First M SR, Gibbon M, Williams J. Structured clinical interview for DSM-IV axis 1 disorders (SCID-1). clinician version American Psychiatric Press. Washington, DC. 1997.
Shafiei R, Riazi R, Sarvghad MR, Galian Sharifdini M, Mahmoodzadeh A, Hajia M. Prevalence of IgG and IgM anti-Toxoplasma gondii antibodies in HIV positive patients in northeast of Iran. Iran J Pathology. 2011; 6(2): 68-72.
Ahmad D, Mehdi S, Sayed HH, Sayed AK, Shirzad G. Serological survey of Toxoplasma gondii in schizophrenia patients referred to Psychiatric Hospital, Sari City, Iran. Trop Biomed. 2010; 27(3): 476-82.
Khademvatan S, Khajeddin N, Izadi S, Yousefi E. Investigation of anti-Toxocara and anti-Toxoplasma antibodies in patients with schizophrenia disorder. Schizophr Res Treatment. 2014; 2014: 230349.
Saraei-Sahnesaraei M, Shamloo F, Jahani Hashemi H, Khabbaz F, Alizadeh SA. Relation between Toxoplasma gondii infections and schizophrenia. IJPCP. 2009; 15(1): 3-9.
Fata A, Elahi R, Berenji F, Zarae R, Ghabouli MJ, Ashrafi Abyaneh H. Evaluation of Immuno- flourescence antibody (IFA) and Immuno-peroxidase Test (IPT) among 200 pregnant women for toxoplasmosis. Med J Mashhad Univ Med Sci. 2001; 44: 16-21.
Sarkari B, Shafiei R, Zare M, Sohrabpour S, Kasraian L. Seroprevalence and molecular diagnosis of Toxoplasma gondii infection among blood donors in southern Iran. J Infect Dev Ctries. 2014; 8(4): 543-7.
Boronow J, Dickerson F, Stallings C, Lee B, Origoni A, Yolken R. HSV-1. CMV and Toxoplasma serology predict cognitive deficits in schizophrenia. Schizophr Res. 2002; 53: 85.
Leweke FM, Gerth CW, Koethe D, Klosterkotter J, Ruslanova I, Krivogorsky B, et al. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004; 254(1): 4-8.
Nascimento FS, de Rosalmeida Dantas C, Netto MP et al. Prevalence of antibodies to Toxoplasma gondii in patients with schizophrenia and mood disorders. Schizophr Res. 2012; 142(1-3): 244-5.
Qiuying L, Xiaonian L. Li L. The control study of schizophrenia and affective disorders and Toxoplasma infections. Acta Academiae Medicinae Hubei. 1999; 20: 223-5.
Torrey EF, Yolken RH. Toxoplasma gondii and schizophrenia. Emerg Infect Dis. 2003; 9(11): 1375-80.
Cetinkaya Z, Yazar S, Gecici O, Namli MN. Anti-Toxoplasma gondii antibodies in patients with schizophrenia--preliminary findings in a Turkish sample. Schizophr Bull. 2007; 33(3): 789-91.
Gu H, Yolken RH, Phillips M, Yange F, Bilder RM, Gilmore JH. Evidence of Toxoplasma gondii infection in recent-onset schizophrenia. Schizophr Res. 2001; 49: 53.
Yolken RH, Bachmann S, Ruslanova I et al. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clin Infect Dis. 2001; 32(5): 842-4.
Alipour A, Shojaee S, Mohebali M, Tehranidoost M, Abdi Masoleh F, Keshavarz H. Toxoplasma infection in schizophrenia patients: a comparative study with control group. Iran J Parasitol. 2011; 6(2):31-7
Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res. 2003; 62(3): 237-44.
| Files | ||
| Issue | Vol 12 No 1 (2017) | |
| Section | Original Article(s) | |
| Keywords | ||
| Toxoplasma gondii Psychiatric patients ELISA | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
